43 peer-reviewed studies. A Nobel Prize. A $60 million state research fund. Decades of safety data. Read it yourself.
Foundational study showing FBZ destabilizes microtubules, triggers p53-mediated apoptosis, and blocks xenograft tumor growth in mice. 605,000+ accesses, 108 citations.
Phase I/II clinical trial reported a 37.5% clinical benefit rate in metastatic triple-negative breast cancer. Presented at ASCO 2025.
Comprehensive protocol combining all three compounds with dosing guidelines. Oxfendazole Phase I data confirms tolerability at doses up to 60 mg/kg.
Most sensitive: ovarian, breast, glioblastoma, lung, colon. Synergistic with docetaxel, cyclophosphamide, and tamoxifen.
800mg three times daily showed tolerability in recurrent glioblastoma patients. First clinical MBZ cancer trial data.
Join the beta to access the full searchable database of 43 peer-reviewed studies.
Join the Beta →